DiBiase Mary's most recent trade in X4 Pharmaceuticals Inc was a trade of 650,000 Common Stock done . Disclosure was reported to the exchange on Feb. 12, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| X4 Pharmaceuticals Inc | Mary DiBiase | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 650,000 | 1,140,980 (7%) | 4% | 0 | Common Stock | |
| X4 Pharmaceuticals Inc | Mary DiBiase | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 61,178 | 513,238 (3%) | 0% | 0 | Common Stock | |
| X4 Pharmaceuticals Inc | Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.45 per share. | 23 Jan 2025 | 22,258 | 490,980 (3%) | 0% | 0.5 | 10,094 | Common Stock |
| X4 Pharmaceuticals Inc | Mary DiBiase | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 230,645 | 519,755 (3%) | 1% | 0 | Common Stock | |
| X4 Pharmaceuticals Inc | Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.57 per share. | 04 Oct 2024 | 67,695 | 452,060 (2%) | 0% | 0.6 | 38,329 | Common Stock |
| X4 Pharmaceuticals Inc | Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.66 per share. | 09 Sep 2024 | 2,642 | 289,110 (1%) | 0% | 0.7 | 1,738 | Common Stock |
| X4 Pharmaceuticals Inc | Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.88 per share. | 11 Mar 2024 | 15,409 | 291,752 (1%) | 0% | 0.9 | 13,591 | Common Stock |
| X4 Pharmaceuticals Inc | Mary DiBiase | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 428,248 | 428,248 | - | - | Stock Appreciation Right | |
| X4 Pharmaceuticals Inc | DiBiase Mary | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 1.01 per share. | 12 Feb 2024 | 3,683 | 307,161 (1%) | 0% | 1.0 | 3,709 | Common Stock |
| X4 Pharmaceuticals Inc | Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 1.89 per share. | 30 Jun 2023 | 464 | 150,536 (0%) | 0% | 1.9 | 877 | Common Stock |
| X4 Pharmaceuticals Inc | Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 1.93 per share. | 23 Jun 2023 | 857 | 151,000 (0%) | 0% | 1.9 | 1,654 | Common Stock |
| X4 Pharmaceuticals Inc | Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 2.23 per share. | 15 Jun 2023 | 857 | 151,857 (0%) | 0% | 2.2 | 1,911 | Common Stock |
| X4 Pharmaceuticals Inc | Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.84 per share. | 10 Mar 2023 | 18,192 | 152,714 (0%) | 0% | 0.8 | 15,281 | Common Stock |
| X4 Pharmaceuticals Inc | Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.93 per share. | 13 Feb 2023 | 4,348 | 170,906 (1%) | 0% | 0.9 | 4,044 | Common Stock |
| X4 Pharmaceuticals Inc | Mary DiBiase | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Nov 2022 | 1,350,000 | 1,350,000 | - | - | Stock Appreciation Right | |
| X4 Pharmaceuticals Inc | Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 17 Aug 2022 | 1,713 | 177,896 (1%) | 0% | - | Common Stock | |
| X4 Pharmaceuticals Inc | Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 30 Jun 2022 | 1,578 | 179,609 (1%) | 0% | - | Common Stock | |
| X4 Pharmaceuticals Inc | Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 24 Jun 2022 | 856 | 181,187 (1%) | 0% | - | Common Stock | |
| X4 Pharmaceuticals Inc | Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 16 Jun 2022 | 856 | 182,043 (1%) | 0% | - | Common Stock | |
| X4 Pharmaceuticals Inc | Mary DiBiase | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 105,000 | 182,899 (1%) | 0% | 0 | Common Stock | |
| X4 Pharmaceuticals Inc | Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 11 Feb 2022 | 12,545 | 77,899 (0%) | 0% | - | Common Stock | |
| X4 Pharmaceuticals Inc | Mary DiBiase | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Sep 2021 | 27,000 | 90,444 (0%) | 0% | 0 | Common Stock |